Abstracts tagged "Biomarkers"

Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
May Choi¹, Farbod Moghaddam¹, Mohammad Sajadi¹, Ann E. Clarke¹, Sasha Bernatsky², Karen Costenbader³, Irene Chen⁴, Murray Urowitz⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul Fortin¹⁵, Dafna Gladman¹⁶, Ian Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald Van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Marvin Fritzler³⁵ and Mina Aminghafari¹, ¹University of Calgary, Calgary, AB, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁴UC Berkeley and UCSF, Berkeley, CA, ⁵Self employed, Toronto, ON, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, South Korea, ⁹The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ¹⁰Krembil Research Institute, Toronto, ON, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Queen's University Belfast, Belfast, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, New York, NY, ²⁰UNC physician network, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburgh, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, CA, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, New York, NY, ²⁷Biobizkaia Health Research Institute, Bilbao, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul, Turkey, ³⁰UC San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Johns Island, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
Abstract Number: 0054 • ACR Convergence 2024
Supernatants from Macrophages Stimulated with Citrullinated and MAA-Modified Fibrinogen Contain PDGF-BB and TGF-b and Upregulate Fibrotic Markers in Human Lung Fibroblasts
Nozima Aripova¹, Michael Duryee¹, Bryant England¹, Carlos Hunter¹, Lauren Klingemann¹, Nigina Aripova², Amy Nelson¹, Jill Poole¹, Dawn Katafiasz¹, Kristina Bailey¹, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²WUSTL, St. Louis, MO
Background/Purpose: Lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD) have greater levels of malondialdehyde-acetaldehyde adducts (MAA) that co-localize with citrullinated (CIT) and…
Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 0505 • ACR Convergence 2024
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
George Karpouzas¹, Lixia Zhang², Mark Zielinski², Brian Cheng² and Sherry Guardiano³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corporation, Keene, NH
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
Abstract Number: 0643 • ACR Convergence 2024
Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE
Nha Nguyen¹, An Vo¹, Chris Tang¹, Erik Anderson², Cynthia Aranow², Betty Diamond³, David Eidelberg¹ and Meggan Mackay⁴, ¹Feinstein Institutes, Manhasset, NY, ²Feinstein Institutes for Medical Research, New York, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
Abstract Number: 0799 • ACR Convergence 2024
Peripheral Biomarker Signatures and a Genetic Risk Score Improve the Identification of RA-ILD Beyond Clinical Risk Factors
Austin Wheeler¹, Thomas Riley², Joshua Baker³, Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Tony Merriman¹², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Hopsital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA that causes substantial morbidity and mortality. Despite the paucity of known risk…
Abstract Number: 0899 • ACR Convergence 2024
Proteomic Insights into JAK Inhibitor Therapeutic Response in Rheumatoid Arthritis
Ting-Shuan Wu¹ and Yi-Ming Chen², ¹Chung Shan Medical University, Taichung, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a common and complex inflammatory polyarthritis. Janus kinase inhibitors (JAKi) have shown superior efficacy compared to traditional treatments, but predictors…
Abstract Number: 1191 • ACR Convergence 2024
Discordant Associations Among Chronological and Biological Age with Multi-joint Osteoarthritis and Symptom Burden: The Johnston County Health Study
Liubov Arbeeva¹, Yvonne Golightly², Cameron Kurz³, Matlock Jeffries⁴, Virginia Kraus⁵, Richard Loeser⁶, Duncan Lascelles⁷ and Amanda Nelson³, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²University of Nebraska Medical Center, Omaha, NE, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Duke University, Durham, NC, ⁶University of North Carolina, Chapel Hill, NC, ⁷North Carolina State University, Raleigh, NC
Background/Purpose: Biological age (BA) may be superior to chronological age (CA) in predicting mortality and age-related conditions such as diabetes and cognitive/functional decline (PMID35715611), as…
Abstract Number: 1463 • ACR Convergence 2024
Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
A. Francesca Setiadi¹, Maggie Burhans², Xuguang Hu², Stephen Colgan³, Kim Notari², Marcia C. Teixeira dos Santos², Apostolos Kontzias², Sue Cheng² and Nehal Mehta⁴, ¹Amgen Inc., South San Francisco, CA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen, Halton Hills, ON, Canada, ⁴The George Washington University School of Medicine, Washington, DC
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with higher rates of obesity and cardiometabolic complications. Apremilast (APR) is an inhibitor of phosphodiesterase 4,…
Abstract Number: 1685 • ACR Convergence 2024
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Minal Aundhia¹, Jinqi Liu², Ellen Cody³, James Rose⁴, Angela Merritt¹, Megan Quinlan-Waters¹, Alyssa Sproles⁵, Sherry Thornton⁵, Prasad Devarajan⁴, Bin Huang⁶ and hermine brunner⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Bristol Myers Squibb, Princeton, NJ, ³Children's Wisconsin, Milwaukee, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁷Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) confers a poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We…
Abstract Number: 2010 • ACR Convergence 2024
The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Austin Wheeler¹, Tanner Ourada², Michael Duryee¹, Bryant England¹, Richard Reynolds³, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and is associated with substantial cardiometabolic morbidity and mortality. In the STOP Gout trial (O’Dell JR…
Abstract Number: 2267 • ACR Convergence 2024
A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Maggie Louie¹, Signe Fransen², Katherine Dilger¹, Kevin Lai¹, Diana Abdueva³, David Chernoff⁴ and Jeffrey Curtis⁵, ¹Aqtual Inc, Hayward, CA, ²Aqtual Inc., sf, CA, ³Aqtual Inc., Hayward, CA, ⁴SetPoint Medical, Sausalito, CA, ⁵University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Current rheumatoid arthritis (RA) treatments, including TNFa inhibitors (TNFi) and JAK inhibitors (JAKi), have transformed the management of RA by controlling symptoms and slowing…
Abstract Number: 2434 • ACR Convergence 2024
ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
Nicole Narayan¹, Joshua Hoffman², Claire Langrish¹, Sibel Ucpinar³, Pedro Corpuz³, Barbara Mittleman⁴ and Mera Tilley², ¹Alumis, South San Francisco, CA, ²Alumis Inc, South San Francisco, CA, ³Alumis, South San Francisco, ⁴Alumis, Inc., San Francisco, CA
Background/Purpose: ESK-001 is a potent, highly selective, oral, allosteric small molecule inhibitor of TYK2 currently being investigated in adults with active SLE in the LUMUS…
Abstract Number: 2661 • ACR Convergence 2024
Changes in Krebs Von Den Lungen 6 Levels (∆KL6) Predict Fibrosing Progression of Interstitial Lung Disease in Patients with an Underlying Connective Tissue Disease (CTD-ILD)
Fredeswinda Romero-Bueno¹, María Carmen Vegas-Sánchez², lydia Abasolo Alcazar³, Mª Jesus Rodriguez Nieto², Cristina Vadillo-Font⁴, M Asuncion Nieto⁵, Laura Cebrián⁶, Belén López-Muñiz⁶, Jesus Loarce Martos⁷, Juan Rigual⁸, hildegarda Godoy Tundidor⁹, Rosalía Laporta¹⁰, Irene Llorente-Cubas¹¹, Gema Bonilla¹², Luis Gomez Carrera¹³, Rosario García-Vicuña¹⁴, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁵ and Olga Sánchez-Pernaute¹⁶, and the NEREA Study group for Autoimmune ILD, ¹Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³IdISSC. HCSC, Madrid, Spain, ⁴Hospital Clinico S Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Madrid, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Servicio de Reumatología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Madrid, Spain, ¹⁰Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹¹Hospital Universitario de La Princesa, Madrid, Spain, ¹²H. Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario La Paz, Madrid, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Madrid, Spain, ¹⁵Hospital Universitario La Princesa, Madrid, Spain, ¹⁶Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is a mucin-1 glycoprotein produced by type 2 alveolar epithelial cells , which increase at peripheral blood show a…
Abstract Number: 0056 • ACR Convergence 2024
Association of Soluble Immune Checkpoint Proteins with the Risk of Developing RA in ACPA-positive At-risk Individuals
Ryo Motoyama¹, Shohei Nakamura¹, Eisuke Inoue², Hideto Takada³, Masayoshi Harigai⁴ and Yuko okamoto¹, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Showa University, Tokyo, Japan, ³Tokyo Women's Medical University, Denver, CO, ⁴International University of Health and Welfare, Tokyo, Japan
Background/Purpose: ACPA+ individuals without inflammatory arthritis are considered as being in an at-risk state of RA, although further factors are needed to identify individuals with…

1
2
3
…
96
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].